catch
life scienc tool diagnost decreas target price
sign irregular cancel trend caught discuss covid-
dynam implic cro industri abnorm
level cancel coincid pandem across industri sponsor
increasingli delay patient enrol new studi start consist data
track industri constitu clinicaltri gov analysi
proactiv convert clinic trial work remot monitor virtual trial
possibl potenti chang order prolong trial could mitig factor
said acknowledg inevit albeit temporarili slow backlog
convers primarili potenti depend durat view
gradual catch-up thereon net/net emphas sustain effort
custom disrupt time issu still lower
nt ep reflect declin top-line growth given
anticip studi start-up delay acknowledg situat remain fluid still
remain confid longer term growth prospect tp drop
lower view risk new busi volatil cancel potenti covid impact
sign recoveri china highlight durabl ta segment
revenu cro side busi bulk studi start-up inevit
delay nt also pull forward work cra regulatori work
importantli experienc bright spot sign recoveri china trial
start ramp back posit read-through broader recoveri across clinic trial
work iqv cso busi may also expos disrupt ta
busi revenu larg tie subscription-bas contract
inher insul view underappreci dynam
lt growth aspir larg intact view exclud view
potenti rel transient headwind relat covid-induc clinic trial delay
continu view iqv medium term growth aspir top-line
ebitda larg intact point chang trial cancel rate
prioriti pharma sponsor compani also remain confid liquid
posit sever lever pull also season dilig cost-cut
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
iqvia inc world largest contract research organ cro
lead healthcar inform technolog servic compani
blue sky scenario support bull sotp
scenario assum cost synergi im merger exceed
expect substanti cross sell cro commerci servic
exist new client greater new project award due broader
diversifi servic offer pronounc strength
spend fundament outsourc demand
grey sky scenario support bear
sotp scenario assum cost synergi take longer
expect captur integration-rel miscu includ
disrupt servic client capit deploy misstep
weaken demand outsourc relev commerci
 close
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
